Alexander Doroshenko is a Canadian infectious disease epidemiologist and public health specialist based in Edmonton, Alberta. He is an assistant professor in the Department of Medicine, Faculty of Medicine and Dentistry at the University of Alberta.[1]
Doroshenko is the public health representative for the AHS COVID-19 Scientific Advisory Group under Alberta Health Services (AHS).[2]
January 9, 2014: “Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)”
November 13, 2020: “What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model”
June 1, 2021: “The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions—Ending the COVID-19 Pandemic”
September 19, 2021: “Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures: Alberta, Canada”
December 2, 2021: “Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review”
Alexander Doroshenko | Public Health. University of Alberta. Retrieved January 8, 2022, from https://www.ualberta.ca/public-health/about/faculty-staff/adjunct-emeritus-faculty/doroshenko.html ↩︎
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf ↩︎